HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia.

AuthorsP Musto, V Simeon, M C Martorelli, M T Petrucci, N Cascavilla, F Di Raimondo, T Caravita, F Morabito, M Offidani, A Olivieri, G Benevolo, R Mina, R Guariglia, G D'Arena, G Mansueto, N Filardi, F Nobile, A Levi, A Falcone, M Cavalli, G Pietrantuono, O Villani, S Bringhen, P Omedè, R Lerose, L Agnelli, K Todoerti, A Neri, M Boccadoro, A Palumbo
JournalLeukemia (Leukemia) Vol. 28 Issue 1 Pg. 222-5 (Jan 2014) ISSN: 1476-5551 [Electronic] England
PMID23958922 (Publication Type: Letter, Research Support, Non-U.S. Gov't)
Chemical References
  • Thalidomide
  • Dexamethasone
  • Lenalidomide
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Dexamethasone (administration & dosage, therapeutic use)
  • Female
  • Humans
  • Lenalidomide
  • Leukemia, Plasma Cell (drug therapy)
  • Male
  • Middle Aged
  • Thalidomide (administration & dosage, analogs & derivatives, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: